Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥28.00 - ¥83.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)2.39M
Market Cap
¥3.30B
Enterprise Value¥369.62M
Total Cash (Recent Filing)¥3.02B
Total Debt (Recent Filing)¥270.00M
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.03
Shares Outstanding113,634,094
10 Day Avg. Volume1,105,300
30 Day Avg. Volume2,390,830
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Gene-regulation PlatformA proprietary gene-regulation platform gives Modalis a differentiated scientific base for developing multiple therapies rather than relying on a single asset. If its approach translates clinically, the platform could support recurring partnering, licensing, or product opportunities over several years.
Focus On High-unmet-need DiseasesTargeting diseases with high unmet medical needs can support meaningful long-term commercial opportunity because effective treatments may address underserved patients and attract strategic interest. This focus also provides a clear rationale for continued development of specialized medicines.
No Reported DebtThe absence of reported debt reduces interest obligations and near-term refinancing pressure, preserving more flexibility than a similarly loss-making biotech with substantial leverage. This provides some balance-sheet protection while Modalis advances its research and pipeline.
Bears Say
Minimal Revenue And Persistent LossesThe lack of meaningful revenue means Modalis has not yet demonstrated commercial traction or operating leverage. Large recurring losses require continued investment before the business can become self-sustaining, leaving results highly dependent on future pipeline progress.
Persistent Cash BurnSustained negative operating and free cash flow indicates that the current business consumes capital rather than generating it. Continued burn can constrain research investment and make the company increasingly reliant on external funding to maintain operations and advance candidates.
Shrinking Equity BaseMaterial equity erosion shows that repeated losses are reducing the financial cushion available to absorb setbacks or fund development. Even without debt, a shrinking capital base can weaken financial flexibility and increase dependence on future capital raising.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥28.00 and its highest was ¥83.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.30B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on Aug 10, 2026. The company reported -¥6.32 earnings per share for the quarter.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 113,634,094 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥6.32 in its last earnings report. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―